Method for preventing abuse of methylphenidate
OwnerKamal K. Midhainventor
Life of this patent
Estimating the term…
Abstract
A method is provided for treating a patient with a methylphenidate-responsive condition that is at a risk of abusing or becoming addicted to methylphenidate. The patient is first evaluated for an elevated risk of drug abuse or addiction through psychological evaluations and then treated with a methylphenidate product that includes an emesis-inducing agent that is inert when ingested orally and only produces emesis when snorted or taken intravenously or a topical analgesic that is inert when ingested orally and only produces irritation when snorted or taken intravenously. The method includes delivering the methylphenidate in a pulsatile delivery system such that the emesis-inducing agent or the topical analgesic is included in one of the pulsatile dosages.
Claims87
A method for reducing the likelihood that a methylphenidate product will be abused, comprising incorporating one of an emesis-inducing agent and a topical analgesic into the methylphenidate product, wherein the emesis-inducing agent and the topical analgesic are inert in oral dosage forms and active only when the methylphenidate is administered non-medically.
A method for treating a methylphenidate-responsive condition in a patient with methylphenidate while minimizing the likelihood that the patient will abuse or become addicted to the methylphenidate, the method comprising:
- (a) determining whether the patient has an elevated risk of abusing or becoming addicted to the methylphenidate and if the determination is that the patient does have an elevated risk of abusing or becoming addicted to the methylphenidate, then,
- (b) treating the methylphenidate-responsive condition by orally administering to the patient a methylphenidate product that includes one of an emesis-inducing agent and a topical analgesic, wherein the emesis-inducing agent and the topical analgesic are inert in oral dosage forms and active only when the methylphenidate is administered non-medically.
A method for treating a methylphenidate-responsive condition in a patient with methylphenidate while minimizing the likelihood that the patient will abuse or become addicted to the methylphenidate, the method comprising:
- (a) determining whether the patient has an elevated risk of abusing or becoming addicted to the methylphenidate and if the determination is that the patient does have an elevated risk of abusing or becoming addicted to the methylphenidate, then,
- (b) treating the methylphenidate-responsive condition by orally administering to the patient, once daily, a pulsatile release dosage form comprised of an immediate release dosage unit and a delayed release dosage unit, each said dosage unit containing a methylphenidate product, wherein following oral administration of the dosage form, a first dose of the methylphenidate product is released substantially immediately from the immediate release dosage unit, followed by a time interval during which substantially no drug is released from the dosage form, and after which time interval a second dose of the methylphenidate product is released from the delayed release dosage unit, and wherein the methylphenidate product includes one of an emesis-inducing agent and a topical analgesic, wherein the emesis-inducing agent and the topical analgesic are inert in oral dosage forms and active only when the methylphenidate is administered non-medically.
A method for treating a methylphenidate-responsive condition in a patient with methylphenidate while minimizing the likelihood that the patient will abuse or become addicted to the methylphenidate, the method comprising:
- (a) determining whether the patient has an elevated risk of abusing or becoming addicted to the methylphenidate and if the determination is that the patient does have an elevated risk of abusing or becoming addicted to the methylphenidate, then,
- (b) treating the methylphenidate-responsive condition by orally administering to the patient, once daily, a pulsatile release dosage form comprised of an immediate release dosage unit and a delayed release dosage unit, each said dosage unit containing a methylphenidate product comprised of d-threo methylphenidate (d-MPH) and substantially no l-threo methylphenidate (l-MPH), wherein following oral administration of the dosage form, a first dose of d-MPH is released substantially immediately from the immediate release dosage unit, followed by a time interval during which substantially no drug is released from the dosage form, and after which time interval a second dose of d-MPH is released from the delayed release dosage unit, and wherein the methylphenidate product includes one of an emesis-inducing agent and a topical analgesic, wherein the emesis-inducing agent and the topical analgesic are inert in oral dosage forms and active only when the methylphenidate is administered non-medically.
Dependencies are inferred from the claim text.